Implications of Study Results Investigating Treatment of Carcinoid Crisis Without Perioperative Octreotide

Video

Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, discusses what the study results demonstrated regarding treating carcinoid crisis without perioperative octreotide for patients with neuroendocrine tumors.

Pharmacy Times interviewed Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, on his presentation at the 2021 NANETS Multidisciplinary Neuroendocrine Tumors Medical Virtual Symposium discussing a prospective study of carcinoid crisis with no perioperative octreotide.

During the interview, Pommier addressed the implications of the prospective study findings in relation to how carcinoid crisis should be prevented and treated now and in the future.

Related Videos
Image credit:  Gorodenkoff | stock.adobe.com
Pharmacist and Patient in Pharmacy | Image Credit: Gorodenkoff - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
hematological cancer/Image Credit: © nikola-master - stock.adobe.com
breast cancer treatment/Image Credit: © Siam - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.